TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Telix Pharmaceuticals ( (AU:TLX) ) has issued an update.
Telix Pharmaceuticals Limited has announced the quotation of new securities on the Australian Securities Exchange (ASX), with a total of 21,815 ordinary fully paid shares being issued. This move is part of the company’s strategic efforts to enhance its capital structure and potentially improve its market position, which could have implications for its stakeholders by increasing the liquidity and visibility of its shares.
The most recent analyst rating on (AU:TLX) stock is a Buy with a A$24.25 price target. To see the full list of analyst forecasts on Telix Pharmaceuticals stock, see the AU:TLX Stock Forecast page.
More about Telix Pharmaceuticals
Telix Pharmaceuticals Limited operates in the biotechnology industry, focusing on the development and commercialization of diagnostic and therapeutic products for cancer and rare diseases. The company is known for its innovative approach in molecularly targeted radiation therapy.
Average Trading Volume: 2,935,168
Technical Sentiment Signal: Sell
Current Market Cap: A$5.13B
For a thorough assessment of TLX stock, go to TipRanks’ Stock Analysis page.